tbuckley/cabot-search huggingface dataset:
What's in a Name?
Authors: Janani Rangaswami
Journal: Annals of Internal Medicine (2014)

On Being a Doctor20 May 2014What's in a Name?Janani Rangaswami, MDJanani Rangaswami, MDFrom Einstein Medical Center, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M13-2834 Audio Reading - “What's in a Name?” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "What's in a Name?," by J. Rangaswami. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Armed with my second cup of coffee and a pager that had a life of its own, I walked into the hospital on Monday morning with trepidation, not knowing what to expect in the aftermath of a long weekend. With relief, I glanced at the patient list that my colleague had typed up over the weekend that showed no major upheavals. Among those admitted for asthma, stroke, and pneumonia, one patient's description caught my eye: a 32-year-old man admitted for palpitations, blurry vision, and weight loss ... severe anemia with a hemoglobin level of 2 g/dL and an enlarged spleen ... Author, Article, and Disclosure InformationAffiliations: From Einstein Medical Center, Philadelphia, Pennsylvania.Corresponding Author: Janani Rangaswami, MD, Einstein Medical Center, 5401 Old York Road, Philadelphia, PA 19141; e-mail, rangaswj[email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “What's in a Name?” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "What's in a Name?," by J. Rangaswami. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 20 May 2014Volume 160, Issue 10Page: 735-736KeywordsAsthmaBloodBlood countsHealth careHeartHospital medicinePneumoniaStrokeVisionWeight loss ePublished: 20 May 2014 Issue Published: 20 May 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Group members differ in relative prototypicality: Effects on the individual and the group
Authors: Michael A. Hogg
Journal: Behavioral and Brain Sciences (2016)

All groups are differentiated into more or less group-prototypical members. Central members readily influence and lead the group, and they define its identity. Peripheral members can feel voiceless and marginalized, as well as uncertain about their membership status - they may engage in extreme behaviors to try to win acceptance. These relative prototypicality dynamics sometimes benefit group performance but sometimes compromise performance.
Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Authors: Laetitia E. Lamberts, Maximillian Koch, Johannes S. de Jong, Arthur L.L. Adams, Jürgen Glatz, Mariëtte E.G. Kranendonk, Anton G.T. Terwisscha van Scheltinga, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. Witkamp, Willem P.Th.M. Mali, Elsken Van der Wall, Paul J. van Diest, Elisabeth G.E. de Vries, Vasilis Ntziachristos, Gooitzen M. van Dam
Journal: Clinical Cancer Research (2016)

Purpose: To provide proof of principle of safety, breast tumor-specific uptake, and positive tumor margin assessment of the systemically administered near-infrared fluorescent tracer bevacizumab-IRDye800CW targeting VEGF-A in patients with breast cancer.Experimental Design: Twenty patients with primary invasive breast cancer eligible for primary surgery received 4.5 mg bevacizumab-IRDye800CW as intravenous bolus injection. Safety aspects were assessed as well as tracer uptake and tumor delineation during surgery and ex vivo in surgical specimens using an optical imaging system. Ex vivo multiplexed histopathology analyses were performed for evaluation of biodistribution of tracer uptake and coregistration of tumor tissue and healthy tissue.Results: None of the patients experienced adverse events. Tracer levels in primary tumor tissue were higher compared with those in the tumor margin (P < 0.05) and healthy tissue (P < 0.0001). VEGF-A tumor levels also correlated with tracer levels (r = 0.63, P < 0.0002). All but one tumor showed specific tracer uptake. Two of 20 surgically excised lumps contained microscopic positive margins detected ex vivo by fluorescent macro- and microscopy and confirmed at the cellular level.Conclusions: Our study shows that systemic administration of the bevacizumab-IRDye800CW tracer is safe for breast cancer guidance and confirms tumor and tumor margin uptake as evaluated by a systematic validation methodology. The findings are a step toward a phase II dose-finding study aimed at in vivo margin assessment and point to a novel drug assessment tool that provides a detailed picture of drug distribution in the tumor tissue. Clin Cancer Res; 23(11); 2730-41. ©2016 AACR.
OP0309 Association of Bone Mineral Density and Carotid Atherosclerosis in Patients with Diabetes Type 2
Authors: V. Vasilkova, T. Mokhort, E. Naumenko
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Many epidemiological studies have shown that low bone mineral density (BMD) and atherosclerosis appear to be related. However, their precise correlation is not completely understood [1,2]. <h3>Objectives</h3> The aim of this study was to examine the relationship between bone mass and carotid measurements in patients with diabetes type 2 (DT2). <h3>Methods</h3> 105 patients both sexes with type 2 diabetes aged 54.69±11.07 years were studied. Control group included 84 healthy subjects the same age. Osteoporosis was defined as a femoral neck BMD T score below -2.5. Carotid intima media thickness (cIMT) and carotid plaque occurrence were determined by B-mode ultrasound and BMD by dual-energy X-ray absorptiometry. The plaques were measured in both common and internal carotid arteries. <h3>Results</h3> BMD and cIMT were inversely associated both in patients and controls. The correlation was stronger in females than in males, and in females, the correlation was stronger after menopause. Patients with DT2, with carotid plaque had higher cIMT at low BMD than at normal BMD, p=0.020. Multiple linear regression analysis reveals that age (p&lt;0.001), smoking (p=0.016), and osteoporosis (p=0.001) were significantly associated with increased cIMT. In women, cIMT was significantly related to age (p=0.01) and osteoporosis (p=0.03). In men, though there was no significant relationship, a trend toward old age and having osteoporosis was observed in increased cIMT (p=0.054, p=0.075). <h3>Conclusions</h3> The association between carotid atherosclerosis and bone metabolism has become an increasing focus of interest in recent years [3], and accumulating evidence has shown that atherosclerosis and osteoporosis frequently co-exist. We found inverse association between BMD and carotid measurements in both diabetic patients and controls. Diabetes type 2 patients, especially postmenopausal women, with decreased BMD may have a higher risk of developing coronary atherosclerosis. <h3>References</h3> Marcovitz PA, Tran HH, Franklin BA et al. Usefulness of bone mineral density to predictsignificant coronary artery disease. AmerJ Cardiol 2005; 96(8): 1059–1063. Mussolino ME, Armenian HK. Low bone mineral density, coronary heart disease, and stroke mortality in men and women: the Third National Health and Nutrition Examination Survey. Annals Epidemiol 2007; 17(11): 841–846. Mitchell G.F., Vita J.A., Larson M.G., Parise H., Keyes M.J., Warner E., Vasan R.S., Levy D., Benjamin E.J. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation. 2005; 112(24): 3722–3728. <h3>Acknowledgement</h3> Thanks to colleagues at our center for technical help and data acquisition. <h3>Disclosure of Interest</h3> None declared
PWE-104 A Randomised Double-Blind Placebo-Controlled Trial of A Multi-Strain Probiotic in The Treatment of Chronic Symptoms Post Diverticulitis
Authors: C Kvasnovsky, AN Donaldson, R Sherwood, I Bjarnason, S Papagrigordiasis
Journal: Gut (2016)

<h3>Introduction</h3> The emergency treatment for acute diverticulitis is straightforward, but many patients develop post-diverticulitis chronic symptoms which resemble that of Irritable Bowel Syndrome (IBS). We assessed the possible effect of Symprove, a multi strain probiotic, on these symptoms in a randomised double-blind placebo-controlled trial. <h3>Methods</h3> This was a single-centre, randomised, double-blind, placebo-controlled trial of the efficacy of the probiotic Symprove in adult patients with post-diverticulitis IBS like symptoms. 143 patients were randomly assigned to receive 1 mL/kg/day of the probiotic (N = 72) or placebo (N = 71) for 3 months. The primary endpoint was a change in abdominal pain. Secondary endpoints included nine abdominal symptoms and changes in faecal calprotectin. <h3>Results</h3> 120 patients completed the trial. Pain score with the probiotic decreased from 9.5±7.7 to 5.9±6.7, which did not differ significantly (<i>P</i> = 0.12) with that of placebo (7.5±7.0 to 6.1±6.4). The probiotic improved constipation, diarrhoea, mucorrhoea, back pain and vaginal discharge significantly (p &lt; 0.04) above that of placebo, but not abdominal pain, PR bleeding, dysuria or bloating. Symprove prevented an increase in intestinal inflammation in male patients (<i>p</i><i> = </i>0.05) <h3>Conclusion</h3> The probiotic Symprove did not improve abdominal pain scores significantly, but significantly improved some other post-diverticulitis symptoms and prevented an escalation in intestinal inflammatory activity in male patients. <h3>Disclosure of Interest</h3> C. Kvasnovsky: None Declared, A. Donaldson: None Declared, R. Sherwood: None Declared, I. Bjarnason Grant/research support from: Received financial support for a SpR for a PhD student (Charlotte), S. Papagrigordiasis Grant/research support from: Recipent of a grant from Symprove for a PhD studentship (Charlotte)
PTU-019 Quality of Upper Gastrointestinal Endoscopy Reporting in Suspected Cancer Patients
Authors: H Measuria, S Greer, M Bhalme
Journal: Gut (2016)

<h3>Introduction</h3> Accurate endoscopy reporting is vital for upper gastrointestinal (GI) cancer management decisions. Effects of poor reporting are unknown but they are likely to cause delay in providing definitive treatment plans. <h3>Methods</h3> The Somerset Upper GI cancer database was used to identify patients between March 2014 and February 2015. Endoscopy report obtained from Endobase, radiological imaging report from PACS and local cancer multi-disciplinary team (MDT) index outcomes were then used to assess reporting quality and draw comparison. Reports were assessed against an expected ideal reporting criteria (anatomic extent of examination and its limitations, tissue samples obtained, description of findings, diagnostic impression and photodocumentation), against which the crucial computed tomography (CT) findings and subsequent MDT decisions could be made. <h3>Results</h3> A 12 month sample size of 84 confirmed upper GI cancer patients were identified (68% males; median age 70 years). Median time difference between endoscopy and staging CT scan was 7 days (range 0–46 days). In 86% (n = 72) the endoscopist reported the exact tumour location when correlated to CT findings. Only 56% (n = 47) mentioned that biopsies had been taken but of these only 51% (n = 24) mentioned the number of biopsies taken. All the visualised lesions had a reported description of how the lesion appeared i.e. malignant features. In total, 19 (23%) patients were identified having repeat gastroscopies and of these 6 (7%) were felt to be avoidable repeats. Of these, 2 were repeated for clarification of previous endoscopy reports while 4 were required due to insufficient biopsies for adequate histological confirmation of cancer. Overall the delay in organising these avoidable repeat gastroscopies ranged from 14–69 days (median 16.5). Of the 6 index gastroscopies that required repeating, 3 were undertaken by GI consultants (two surgeons, one physician), 1 trainee endoscopist, 1 nurse endoscopist, 1 acute physician consultant endoscopist. <h3>Conclusion</h3> Poor endoscopy reporting practice can cause significant delays in cancer diagnosis and management. Some technical difficulties are inevitable in clinical practice however attention to details in report is important. We recommend that every endoscopy unit must ensure that regular internal audits on endoscopy reporting are undertaken for quality assurance. <h3>Disclosure of Interest</h3> None Declared
THU0274 Upregulation of NOD2 Involved in The Inflammatory Response by Activation of MAPK Signaling Pathway in Lupus Nephritis
Authors: O. Jin, C.C. Hou, X.Q. Li, X. Zhang, M. Qiu, D. Lin, L. Fang, X. Guo, Z. Lin, Z. Liao, J. Gu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Nucleotide-binding oligomerization domain (NOD) - containing 2 (NOD2) is a NOD - like receptors (NLRs) which plays important role in immune regulation and inflammatory response. There are increasing evidences to show that NOD2 may contribute to the development of numerous auto inflammatory and autoimmune disorders. However, their role in lupus nephritis (LN) is not known. Here, we explored the role of NOD2 in LN. <h3>Objectives</h3> However, their role in lupus nephritis (LN) is not known. Here, we explored the role of NOD2 in LN. <h3>Methods</h3> Immunohistochemistry was applied to observe the expression of NOD2 in renal biopsies. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the level of NOD2 mRNA in the biopsies. In vitro studies, HK-2 cells (renal tubular epithelial cell-line) were cultured with different inflammatory stimulation, western blot was used to investigate their expression of NOD2 and the following activation of MAPK pathway signals (ERK1/2, p38 and JNK), real-time qPCR was applied to observe the mRNA levels of downstream pro-inflammatory mediators (IL-1b, IL-8, MCP-1, TGF-b1, IL-6). <h3>Results</h3> (1) Immunohistochemistry staining demonstrated that the expression of NOD2 in LN is higher than that of normal control (P=0.002), and the mRNA level of NOD2 in renal tissue of LN patients was higher than that of normal control (P=0.001). (2) In vitro studies, the urine and serum from onset LN patients can significantly promote higher NOD2 expression in HK2 cells than that from healthy control (P&lt;0.001). In addition, TGF-b1, LPS and muramyl dipeptide (MDP) can also induce higher NOD2 expression in HK2 cells (P&lt;0.001, respectively). (3) The activation of NOD2 increased phosphorylation of ERK1/2, p38 and JNK. Moreover, the activation of NOD2 induced the release of pro-inflammatory mediators including IL-1b, IL-8, MCP-1, TGF-b1, IL-6. <h3>Conclusions</h3> Our study showed NOD2 expression was increased in LN patients. The activation of NOD2 can promote the activation of MAPK signaling pathway and release of downstream pro-inflammatory mediators. NOD2 may participate in the pathogenesis of LN. <h3>Disclosure of Interest</h3> None declared
AB0769 Assessment of Sequels of poliomyelitis in Hips by 3D-DXA
Authors: A. Erra, D. Grados, L. Lopez-Vives, Y. Martelli, L. Humbert, A. Pasarin, N. Allue, S. Di Gregorio, L. del Rio
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Polio is a devastating infectious disease that causes paralysis and severe muscular atrophy. When any of the legs is affected, a low aBMD at the corresponding hip is a common finding in DXA measurement. <h3>Objectives</h3> to study the influence of polio consequences on volumetric bone density and cortical thickness using the 3D-DXA technology. <h3>Methods</h3> 22 patients of both sexes suffering post-polio syndromes (mean age 57±uffering pos were scanned using a GE iDXA system and both proximal femurs were reconstructed using the 3D-DXA technology. 3D-DXA is based on the registration of a 3D statistical model of the femoral shape and density onto the 2D DXA image and provides measurements of volumetric BMD (vBMD) and BMCof the trabecular and cortical bone as well as a quantification of the cortical thickness. The measurements at the leg affected by polio were compared by t-test with those at the non-affected leg. <h3>Results</h3> Trabecular BMC was 22% lower (-1.8 g, p&lt;0.01) and cortical BMC 19% lower (-2.9 g, p&lt;0.01) at the polio leg (total hip region). Similar findings were observed for the vBMD: 18% decrease (-0.020 g/cm<sup>3</sup>, p&lt;0.01) at the trabecular region and a 2.3% decrease for the cortical bone (-0.024 g/cm<sup>3</sup>, p&lt;0.01). The proximal femur volume was also inferior (-12%, -9 cm<sup>3</sup>, p&lt;0.01). The cortical thickness was thinner at the polio leg (-12%, -0.2 mm, p&lt;0.01). <h3>Conclusions</h3> A long period of decreased of mechanical charges, low muscle strength, postural imbalance has dramatic consequences on bone development. The analyses performed using the 3D-DXA technology indicates an overall impairment of cortical and trabecular BMD and a significant decrease of the cortical thickness. <h3>Disclosure of Interest</h3> None declared
Interventional Intensification of Chemotherapy Prior to Hematopietic Stem Cell Transplantation Reduces Residual Leukemia but Does Not Improve Survival in Children with Relapsed Acute Lymphoblastic Leukemia
Authors: Cornelia Eckert, Christiane Chen-Santel, Christina Peters, Thomas Klingebiel, Bernd Gruhn, Rupert Handgretinger, Guenter Henze, Arend von Stackelberg
Journal: Blood (2014)
C/EBPα and MiR-182 Generate a Negative Feedback Loop Which Is Dysregulated in Acute Myeloid Leukemia
Authors: Alexander Arthur Wurm, Dennis Gerloff, Daniela Braeuer-Hartmann, Christiane Katzerke, Jens-Uwe Hartmann, Stephan Fricke, Nadja Hilger, Meritxell Alberich-Jorda, Daniel G Tenen, Dietger Niederwieser, Gerhard Behre
Journal: Blood (2014)
SAT0641-HPR Reasons To Stop Drinking Alcohol among Patients with Rheumatoid Arthritis – A Mixed Method Study
Authors: M. Andersson, I. Larsson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Studies of alcohol use in patients with rheumatoid arthritis are sparse and studies of why patients choose to stop drinking alcohol in particular <h3>Objectives</h3> The aim of the current study was twofold: first to identify patients with RA who stopped drinking alcohol and compare those to patients drinking alcohol, and second, to explore reasons to stop drinking alcohol. <h3>Methods</h3> In 2010 a self-completion postal questionnaire was sent to all 2,102 prevalent patients in the Better anti-rheumatic farmacotherapy (BARFOT) study enquiring about disease severity, physical function (HAQ) and health related quality of life (EQ5D), pain, fatigue, patient global assessment (PatGA) and lifestyle factors e.g. alcohol. The questions assessing alcohol included the question “Have you stopped drinking alcohol?” and an open question “Why have you stopped drinking alcohol?” A mixed method design was used and 1512 patients had answered the alcohol questions and was included in the study of those 86 had stopped drinking alcohol. Seventy-one patients answered the open question and their answers were analyzed with qualitative content analysis (1). <h3>Results</h3> Comparing patient with RA using alcohol or not, the patients who stopped drinking alcohol was older median age (min-max) 69 (36–90) vs. 66 (23–95), p=0.011, more men 42% vs. 29%, p=0.015, had worse physical function, median HAQ (min-max) 0.50 (0–3.00) vs. 1.00 (0–2.75), p&lt;0.001, worse health related quality of life, median EQ5D (min-max), 0.69 (-0.59–1.00) vs. 0.76 (-0.02–1.00), p&lt;0.001, worse self-perceived health, median PatGA (min-max) 5 (0–10) vs. 3 (0–10), &lt;0.001, more pain, median (min-max) 5 (0–10) vs. 3 (0–10), p&lt;0.001, and more fatigue median (min-max) 6 (0–10) vs 4 (0–10), p&lt;0.001. There were no differences between the groups regarding disease duration, swollen and tender joints. The qualitative content analysis resulted in five categories describing the reasons for patient with RA to stop drinking alcohol: disease and treatment, health and wellbeing, work and family, faith and belief and dependences and abuse <h3>Conclusions</h3> Patients with RA who stopped drinking alcohol have a lower physical function, health related quality of life, self-perceived health and more pain and fatigue comparing to patients with RA drinking alcohol. The reasons to stop drinking alcohol were of different nature such as medical, physical, mental, social and spiritual <h3>References</h3> Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse education today. 2004 Feb; 24(2):105–112. <h3>Disclosure of Interest</h3> None declared
Decitabine Low-Dose Schedule (100 mg/m2/course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.
Authors: Hagop M. Kantarjian, Farhad Ravandi, Susan O’Brien, Francis Giles, Stefan Faderl, Guillermo Garcia-Manero, Jan Davis, Elihu Estey, Jean-Pierre Issa.
Journal: Blood (2004)
A Comprehensive Study of the VHL-R200W Chuvash Polycythemia Mutation Reveals a Gradual Dysregulation of the Hypoxia Pathway in Oncogenesis
Authors: Betty Gardie, Sophie Couvé, Charline Ladroue, Elodie Laine, Karène Mahtouk, Justine Guégan, Sophie Gad, Hélène Le Jeune, Bernard Lecomte, Jean-Christophe Pagès, Patrick Benusiglio, Brigitte Bressac-de Paillerets, Jean Feunteun, Philippe Dessen, Sylvie Hermouet, Luba Tchertanov, David R. Mole, William G. Kaelin, Peter J Ratcliffe, Stephane Richard
Journal: Blood (2014)
SP0081 Imaging in The Management of Gout. Clinical Tool or Endpoint?
Authors: N. Dalbeth
Journal: Annals of the Rheumatic Diseases (2016)

Imaging techniques can identify the core features of disease in gout: urate crystal deposition, joint inflammation and structural damage. Clinical applications include detection and measurement of urate crystal deposition using high resolution ultrasonography (US) and dual energy computed tomography (DECT), assessment of disease severity to guide treatment decisions, and detection of disease complications (eg. structural damage, tendon disease, concomitant infection). Although imaging modalities such as US and DECT are increasingly used for gout diagnosis in clinical practice, there are uncertainties about interpretation of results in asymptomatic hyperuricaemia, the sensitivity of these methods in early disease, artefact issues, and reliability. Imaging techniques also have potential to assess response to treatment, both in clinical practice and in research settings. Key questions remain about the sensitivity to change of urate crystal deposition, inflammation and joint damage using imaging techniques. Imaging techniques that allow visualisation of urate crystal deposition may play a particularly important role in patient understanding of disease and promoting engagement with long-term urate-lowering treatments. <h3>Disclosure of Interest</h3> None declared
Vaccination With Irradiated Induced Pluripotent Stem Cells Genetically Engineered To Produce GM-CSF Confers Potent T Cells-Mediated Antitumor Immunity
Authors: Hiroyuki Inoue, Ayumi Watanabe, Chika Sakamoto, Megumi Narusawa, Takafumi Hiramoto, Shohei Miyamoto, Makoto Inoue, Koichi Takayama, Mamoru Hasegawa, Yoichi Nakanishi, Kenzaburo Tani
Journal: Blood (2013)